Title
Category
Credits
Event date
Cost
  • Myasthenia Gravis
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Patients with generalized myasthenia gravis (gMG) receive multiple immunosuppressive therapies, but with incomplete suppression of IgG autoantibodies. Read this rapid update in gMG to learn about novel therapies that can more effectively suppress IgG autoantibodies through a novel mechanism of action to help your patients achieve better clinical outcomes.
  • Child and Adolescent Psychiatry
  • COVID-19
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Long COVID symptoms are both physical and mental in nature among children and adolescents and have the potential to affect long-term functioning and increase the overall burden on health care delivery.
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • Neuroimaging
  • Patient/Physician Communication
  • Primary Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Prompt treatment of early-stage Alzheimer disease (AD) can curb symptom progression. Tests for biomarkers, new symptomatic treatments and disease-modifying agents, and the addition of the preclinical stage to AD diagnostic criteria can aid in earlier disease recognition and building treatment plans.
  • Rett Syndrome
  • Child and Adolescent Psychiatry
  • Movement Disorders
  • Neurology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Because of the multiple comorbidities associated with Rett syndrome, clinicians are advised to incorporate clinical guidelines that suggest implementing therapeutics with a multidisciplinary approach and with an eye toward new and emerging therapies. 
  • Bipolar Disorder
  • Depression
  • Antipsychotics
  • Movement Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In brief videos, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia (TD), how to observe patients (whether in person or via telemedicine), and how to educate patients and families about TD.
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Neurology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Navigating the associated differential diagnosis in AD is essential as various causes of cognitive impairment require different treatment strategies.
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Neurology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Among the most transformative Alzheimer Disease discoveries is the existence of biomarkers which can manifest decades before onset of disease-related dementia.
  • Rett Syndrome
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Because of the multiple comorbidities and symptoms associated with Rett syndrome, clinicians are advised to implement a multidisciplinary approach to disease management with an eye toward new and emerging therapies on the horizon.

Pages